The Power of PrEP
To mark National Black HIV/AIDS Awareness Day on February 7, Treatment Action Group (TAG) is co-hosting a webinar “The Power of PrEP” in coalition with PrEP4All, Atlanta Black Women, AVAC, and iStrive.
Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEPFAR COPs
On January 24, 2022, Treatment Action Group (TAG), World Hepatitis Alliance (WHA), Harm Reduction International (HRI), the International Network of People Who Use Drugs (INPUD), and the International Drug Policy Consortium (IDPC) will host a webinar, “Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEFPFAR COPs."
Open Letter: Urgent Action Necessary to Improve Equitable Access to Bedaquiline-Based Regimens and Achieve 1/4/6×24
TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…
Risk of Breakthrough COVID-19 Infections and Disease in Vaccinated People with HIV
This fact sheet on breakthrough COVID-19 infections among people living with HIV was co-produced by TAG and our partners the Black AIDS Institute, Southern AIDS Coalition and the COVID-19 Prevention Network.
1/4/6×24 Community Campaign Training Materials
Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…
Public Comment Submitted to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)
Comment submitted prior to their meeting on November 17, 2022. Comment is in regard to discussion and voting on recommendation related to implementation of the HIV Organ Policy Equity (HOPE) Act of 2013, specifically pertaining to HIV-positive to HIV-positive organ transplantation and pertaining to the following draft recommendation under consideration regarding removal of the statutory “NIH Research Criteria and IRB” requirement.
TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.